Compounds > ecteinascidin 743
Page last updated: 2024-09-02

ecteinascidin 743 and ER-Negative PR-Negative HER2-Negative Breast Cancer

ecteinascidin 743 has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blum, JL; Conte, P; Cullell-Young, M; Debled, M; Delaloge, S; Efrat, N; Gonçalves, A; Lardelli, P; Nieto, A; Richards, D; Richards, PD1

Trials

1 trial(s) available for ecteinascidin 743 and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.
    Breast cancer research and treatment, 2016, Volume: 155, Issue:2

    Topics: Adult; Aged; Dioxoles; Disease-Free Survival; Humans; Middle Aged; Receptor, ErbB-2; Tetrahydroisoquinolines; Trabectedin; Triple Negative Breast Neoplasms; Young Adult

2016